FIELD: medicine, oncology, pharmacy.
SUBSTANCE: invention describes a medicament used in treatment of liver disease by prevention of invasion onset of portal vein. This agent represents the effective medicament containing menatetrenone as an active component used in treatment/prophylaxis of liver disease. Indicated agent used in treatment/prophylaxis of liver disease is the effective medicament against liver cancer, in particular, against DCP (des-γ-carboxyprothrombin)-positive liver cancer. Agent used in aims for treatment/prophylaxis of liver disease contains menatetrenone as an active component, it improves prognosis significantly after carrying out the anticancer therapy and possesses the excellent effect directed on prevention of liver cancer relapses.
EFFECT: valuable medicinal property of agent.
4 cl, 2 tbl, 10 dwg, 2 ex
| Title | Year | Author | Number |
|---|---|---|---|
| METHOD FOR DETERMINING THE RISK OF HEPATOCELLULAR CARCINOMA IN THE PATIENTS WITH CHRONIC HEPATITIS C | 2019 |
|
RU2723891C1 |
| METHOD FOR PREDICTION OF RISK OF DEVELOPMENT OF HEPATOCELLULAR CARCINOMA IN PATIENTS WITH CHRONIC HEPATITIS C | 2020 |
|
RU2749117C1 |
| GPC3-TARGETED DRUG WHICH IS ADMINISTERED TO PATIENT SENSITIVE TO GPC3 DRUG-TARGETING THERAPY | 2013 |
|
RU2707882C2 |
| METHOD FOR DIAGNOSING HEPATOCELLULAR CARCINOMA CASES | 2003 |
|
RU2319969C2 |
| METHODS FOR MODULATING BILE ACID HOMEOSTASIS AND TREATMENT OF BILE ACID DISORDERS AND DISEASES | 2013 |
|
RU2675514C2 |
| SORAFENIB-BASED COMBINATION THERAPY FOR HEPATOCELLULAR CARCINOMA | 2022 |
|
RU2800071C1 |
| ACTIVATED FOAM MATERIAL (VERSIONS) | 2005 |
|
RU2343901C2 |
| FUCOSIDASE INHIBITORS | 2016 |
|
RU2765202C2 |
| 6-OXO-1,6-DIHYDRO-PYRIDAZINE DERIVATIVE FOR USE IN TREATMENT OF HEPATOCELLULAR CARCINOMA (HCC) | 2013 |
|
RU2650679C2 |
| COMBINED PRODUCT CONTAINING DICYCLOPLATIN AND METHOD FOR ITS PRODUCTION AND USE | 2018 |
|
RU2784809C2 |
